Calidi BiotherapeuticsCLDI +5.35%12 EV-to-EBIT is 0.08 as of Jul. 09, 2026. GuruFocus rates CLDI with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 366 Biotechnology companies, Calidi Biotherapeutics ranks better than 95.9% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Calidi Biotherapeutics's Enterprise Value for the quarter that ended in Mar. 2026 was $-1.56 Mil.
Calidi Biotherapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-18.92 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Calidi Biotherapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Calidi Biotherapeutics EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Calidi Biotherapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Calidi Biotherapeutics's EV-to-EBIT falls into.
Calidi Biotherapeutics's current Enterprise Value is $-1.48 Mil.
Calidi Biotherapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-18.92 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Calidi Biotherapeutics (CLDI) has a EV-to-EBIT of 0.08 as of Jul. 09, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Calidi Biotherapeutics and its competitors. According to the industry distribution chart, Calidi Biotherapeutics ranks #15 out of 366 companies in the Biotechnology industry, placing it in the top 4.1%.
Is Calidi Biotherapeutics' EV-to-EBIT too high?
Calidi Biotherapeutics' current EV-to-EBIT is 0.08. The Biotechnology industry median EV-to-EBIT is 14.63. Calidi Biotherapeutics' value of 0.08 is 99.5% below this industry median. Based on the distribution chart, Calidi Biotherapeutics ranks #15 out of 366 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Calidi Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Calidi Biotherapeutics' EV-to-EBIT compare to DCOY and CDT?
According to the Biotechnology industry distribution chart, Calidi Biotherapeutics ranks #15 out of 366 companies for EV-to-EBIT. This places Calidi Biotherapeutics in the top 4% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 14.63. Calidi Biotherapeutics' value of 0.08 is 99.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 14.63, based on 366 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Calidi Biotherapeutics's current EV-to-EBIT of 0.08 is 99.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Calidi Biotherapeutics and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 14.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Calidi Biotherapeutics's current EV-to-EBIT is 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Calidi Biotherapeutics stock overvalued right now?
Calidi Biotherapeutics (CLDI) has a current EV-to-EBIT of 0.08. The current EV-to-EBIT is 0.08 and 99.5% below the Biotechnology industry median of 14.63. Calidi Biotherapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Calidi Biotherapeutics (CLDI), the current EV-to-EBIT is 0.08 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
12GF Score
Get the complete analysis for CLDI
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLDI has been successfully added to your 
